Nardosinone regulates the slc38a2 gene to alleviate Parkinson's symptoms in rats through the GABAergic synaptic and cAMP pathways

Li-hua Bian,Zi-wei Yao,Zhe-yi Wang,Xiao-mei Wang,Qiu-yu Li,Xue Yang,Jia-yuan Li,Xiao-jia Wei,Guo-hui Wan,Yu-qing Wang,Jin-li Shi,Jian-you Guo
DOI: https://doi.org/10.1016/j.biopha.2022.113269
2022-09-01
Abstract:In a rotenone-induced Parkinson’s disease (PD) rat model, behavioral investigation, pathological examination, inflammatory factor analysis, and mitochondrial structure and function investigation verified the anti-PD efficacy of nardosinone. A combined transcriptome and proteome analysis proposed that the anti-PD target of nardosinone is the slc38a2 gene and may involve the GABAergic synaptic pathway and cAMP-signaling pathway. Analysis of targeted slc38a2 knockout cells and expression of key enzyme-encoding genes in both pathways verified the target and pathways proposed by the ‘omics analysis. This further confirms that nardosinone can regulate the slc38a2 gene, a potential new target for the treatment of Parkinson's disease, and plays an anti-PD role through the GABAergic synaptic and cAMP pathways.
pharmacology & pharmacy,medicine, research & experimental
What problem does this paper attempt to address?